Alglucerase是从人体胎盘中制备的糖蛋白酶糖脑甙酶(glucocerebrosidase)的一种改变形式。最近美国FDA批准此药用于治疗患有高歇氏病(Ⅰ型)非神经型病人。高歇氏病患高歇氏病的病人有先天性糖脑甙酶活性缺乏和糖基神经酰胺(glucosylceramide)的聚积,这是鞘脂类的最终代谢产物,在网状内皮细胞的溶酶体中,尤其在巨噬细胞内更为明显。这些被塞满脂类 Alglucerase is a modified form of the glucocerebrosidase prepared from human placenta. The FDA recently approved the drug for the treatment of patients with Gaucher’s disease (type I) non-neuronal. Patients with Gaucher’s disease with Gaucher’s disease have a congenital absence of glucokinase activity and accumulation of glucosylceramides, which are the final metabolites of sphingolipids, are present in lysosomes of reticuloendothelial cells Especially in macrophages. These are stuffed with lipids